Literature DB >> 22311561

Diagnosis, management and outcomes of adults hospitalized with influenza.

Nelson Lee1, Michael G Ison.   

Abstract

Annual influenza epidemics and periodic pandemics result in excess hospital admissions. Hospitalization typically occurs in those with underlying medical conditions, those at the extremes of age and in pregnant woman; young adults and obese individuals were also at increased risk during the 2009 H1N1 pandemic. Severe influenza pneumonia, exacerbation of underlying lung diseases, cardiovascular and cerebrovascular events and bacterial superinfection are common reasons for hospitalization. Clinical diagnosis is unreliable and virological confirmation can be challenging. Overall mortality among adults hospitalized with influenza ranges from 4% to 8%, although higher mortality (>10-15%) may be seen during pandemics and among the immunocompromised. Recent data have suggested that neuraminidase inhibitors, particularly when given early, can accelerate viral clearance and improve clinical outcomes in hospitalized adults; thus, antiviral treatment should be considered in all cases. Controlled clinical trials are urgently needed in this population to evaluate comparative treatment efficacy of different agents and combinations, including emergence of antiviral resistance, and to address issues related to dosage, duration and parenteral route.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22311561     DOI: 10.3851/IMP2059

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  26 in total

1.  Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.

Authors:  Rong Deng; Ai Ping Lee; Mauricio Maia; Jeremy J Lim; Tracy Burgess; Priscilla Horn; Michael A Derby; Elizabeth Newton; Jorge A Tavel; William D Hanley
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

2.  Emerging infections of the central nervous system.

Authors:  Jennifer Lyons; Justin McArthur
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

3.  Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.

Authors:  Jacqueline M McBride; Jeremy J Lim; Tracy Burgess; Rong Deng; Michael A Derby; Mauricio Maia; Priscilla Horn; Omer Siddiqui; Daniel Sheinson; Haiyin Chen-Harris; Elizabeth M Newton; Dimitri Fillos; Denise Nazzal; Carrie M Rosenberger; Maikke B Ohlson; Rob Lambkin-Williams; Hosnieh Fathi; Jeffrey M Harris; Jorge A Tavel
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 4.  Clinical use of approved influenza antivirals: therapy and prophylaxis.

Authors:  Michael G Ison
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

5.  A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.

Authors:  Jeremy J Lim; Michael A Derby; Yaping Zhang; Rong Deng; Richard Larouche; Malia Anderson; Mauricio Maia; Stéphanie Carrier; Isabelle Pelletier; Johanne Girard; Priya Kulkarni; Elizabeth Newton; Jorge A Tavel
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  Clinical and virologic factors associated with reduced sensitivity of rapid influenza diagnostic tests in hospitalized elderly patients and young children.

Authors:  Martin C W Chan; Nelson Lee; Karry L K Ngai; Ting F Leung; Paul K S Chan
Journal:  J Clin Microbiol       Date:  2013-11-27       Impact factor: 5.948

7.  A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.

Authors:  Bindumadhav M Marathe; Heba H Mostafa; Peter Vogel; Philippe Noriel Q Pascua; Jeremy C Jones; Charles J Russell; Richard J Webby; Elena A Govorkova
Journal:  Antiviral Res       Date:  2017-10-31       Impact factor: 5.970

8.  A cost-effectiveness analysis of "test" versus "treat" patients hospitalized with suspected influenza in Hong Kong.

Authors:  Joyce H S You; Eva S K Chan; Maggie Y K Leung; Margaret Ip; Nelson L S Lee
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

Review 9.  The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews.

Authors:  Barbara Michiels; Karolien Van Puyenbroeck; Veronique Verhoeven; Etienne Vermeire; Samuel Coenen
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

Review 10.  Clinical Implications of Antiviral Resistance in Influenza.

Authors:  Timothy C M Li; Martin C W Chan; Nelson Lee
Journal:  Viruses       Date:  2015-09-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.